Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
AuteursJhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, García Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruíz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
AuteursAftimos PG, Wiedig M, Fontsa ML, Awada A, Ghanem G, Journe F
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
AuteursAftimos PG, Wiedig M, Fontsa ML, Awada A, Ghanem G, Journe F
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
AuteursAftimos PG, Wiedig M, Fontsa ML, Awada A, Ghanem G, Journe F
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
AuteursAftimos PG, Wiedig M, Fontsa ML, Awada A, Ghanem G, Journe F
